Pds biotech releases white paper detailing the potential of the versamune® platform in overcoming a major limitation of immuno-oncology

Promotes in-vivo tumor-attacking killer t-cells to facilitate cancer treatment promotes in-vivo tumor-attacking killer t-cells to facilitate cancer treatment

PDSB Ratings Summary

PDSB Quant Ranking